JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M309772200 on September 26, 2003

J. Biol. Chem., Vol. 278, Issue 48, 47898-47904, November 28, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
278/48/47898    most recent
M309772200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kjær, S.
Right arrow Articles by Ibáñez, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kjær, S.
Right arrow Articles by Ibáñez, C. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Identification of a Surface for Binding to the GDNF-GFR{alpha}1 Complex in the First Cadherin-like Domain of RET*

Svend Kjær and Carlos F. Ibáñez{ddagger}

From the Division of Molecular Neurobiology, Department of Neuroscience, Karolinska Institute, 171 77 Stockholm, Sweden

Received for publication, September 3, 2003 , and in revised form, September 24, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The RET receptor tyrosine kinase is activated by binding to a ligand complex formed by a member of the glial cell line-derived neurotrophic factor (GDNF) family of neurotrophic factors bound to its cognate GDNF-family receptor-{alpha} (GFR{alpha}) glycosylphosphatidylinositol-linked co-receptor. Molecular modeling studies of the extracellular domain of RET (RETECD) have revealed the existence of four cadherin-like domains (CLD1–4) followed by a cysteine-rich domain. Cross-linking experiments have indicated that the RETECD makes direct contacts with both the GDNF ligand and GFR{alpha}1 molecule in the complex, although it has low or no detectable affinity for either component alone. We have exploited sequence and functional divergences between the ectodomains of mammalian and amphibian RET molecules to map binding determinants in the human RETECD responsible for its interaction with the GDNF-GFR{alpha}1 complex by homologue-scanning mutagenesis. We found that Xenopus RETECD was unable to bind to GDNF-GFR{alpha}-1 or neurturin (NTN)-GFR{alpha}-2 complexes of mammalian origin. However, a chimeric molecule containing CLD1, -2, and -3 from human RETECD, but neither domain alone, had similar binding activity as compared with wild type human RETECD, suggesting the existence of an extended ligand binding surface within the three N-terminal cadherin-like domains of human RETECD. Subsequent loss-of-function experiments at higher resolution identified three small subsets of residues, mapping on the same face of the molecular model of RET CLD1, that were required for the interaction of human RETECD with the GDNF-GFR{alpha}1 complex. Additional experiments demonstrated that N-linked glycosylation of human RETECD was not required for ligand binding. Based on these observations, we propose a model for the assembly and architecture of the GDNF-GFR{alpha}1-RET complex.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Glial cell line-derived neurotrophic factor (GDNF)1 was initially identified as a potent survival factor of ventral midbrain dopaminergic neurons (1) and has since its discovery been intensely studied due to its potential utility as a therapeutic agent for the treatment of neurodegenerative diseases, such as Parkinson's disease (2). GDNF is a disulfide-linked homodimer consisting of two polypeptide chains of about 110 residues each. The overall disulfide arrangement of GDNF conforms to the structural cystine knot motif (3). Sequence and structural similarities have indicated that GDNF is a distant member of the transforming growth factor-{beta} superfamily of ligands. However, unlike typical members of this family that signal through receptor serine-threonine kinases, GDNF signals through a receptor complex formed by the receptor tyrosine kinase RET and a glycosylphosphatidylinositol-anchored, ligand binding moiety, the GDNF family receptor {alpha}1 (GFR{alpha}1). Four structurally related but distinct ligands, namely GDNF, neurturin (NTN), persephin, and artemin, utilize RET as signaling receptor with the aid of four different GFR{alpha} receptors (GFR{alpha}1–4), which confer ligand specificity (4, 5). In addition, an alternative receptor complex for GDNF family ligands, involving the neural cell adhesion molecule in collaboration with GFR{alpha} proteins, has recently been identified (6).

Both gain- and loss-of-function mutations in the RET gene have been identified in human diseases. Mutations inducing constitutive dimerization or activation of the RET tyrosine kinase lead to familial and sporadic cancers in neuroendocrine organs, including multiple endocrine neuroplasias type 2A and 2B and familial medullary thyroid carcinoma (7, 8). Loss-of-function mutations in RET cause a dominant genetic disorder of neural crest development known as Hirschsprung disease, which results in a lack of neurons in distal segments of the enteric nervous systems and colon aganglionosis (9). Although RET has no detectable affinity for any of the GDNF family ligands in the absence of GFR{alpha} receptors, chemical cross-linking and co-immunoprecipitation experiments have indicated that RET can still make direct contacts with both the GDNF and GFR{alpha}1 molecules in the complex (10–12). A structural and functional understanding of the protein-protein interactions at play in the GDNF-GFR{alpha}1-RET ternary complex is still lacking and will be required for the rational design of small molecules capable of mimicking the effects of GDNF.

The binding determinants that mediate the interaction between GDNF family ligands and GFR{alpha} molecules have been investigated using different approaches, including alanine and homologue-scanning mutagenesis (12–14). Key residues involved in the interaction with GFR{alpha} receptors were found in the two {beta}–hairpin "fingers" of the GDNF molecule (13, 14). Intriguingly, residues at analogous positions have been shown to participate in the interaction of classical transforming growth factor-{beta} proteins with their cognate type II receptors (15). The major determinant of ligand binding in GFR{alpha} molecules has been localized to the most conserved region of the molecule, a central domain predicted to contain four conserved {alpha}-helices and two short {beta}-strands (12). Distinct hydrophobic and positively charged residues in this central region were required for the binding of GFR{alpha}1 to GDNF (12). Because the RETECD is unable to bind members of the GDNF family directly, and only weakly to GFR{alpha} molecules (16), this receptor is likely to interact with a composite surface formed by residues from both GDNF and GFR{alpha} molecules. However, the regions and residues in RETECD that participate in these interactions have remained unknown.

The overall molecular architecture of the RETECD was recently elucidated using a bioinformatics approach (17). In that study, it was found that the RETECD comprises four N-terminal domains with similarity to classical cadherin molecules, so-called cadherin-like domains or CLDs, followed by a C-terminal cysteine-rich domain. Multiple alignments indicate that the RETECD from a number of different species, including human, mouse, chick, frog, fish, and fly, appear to conform to this organization (17). The highest degree of sequence similarity between the RETECD and cadherins is found in and around a highly conserved calcium binding site present between CLD2 and CLD3 but, unlike classical cadherins, absent between all other RETECD subdomains (17).

In the present study, we have investigated the location and biochemical characteristics of ligand binding determinants in the human RETECD. For this purpose, we have employed homologue-scanning mutagenesis, taking advantage of the inability of the Xenopus RETECD to interact with complexes between GDNF family ligands and GFR{alpha} molecules of mammalian origin, despite its overall structural similarity to the human RETECD.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
DNA Constructs—All expression constructs were generated in the pSecTag2AHA system (18). The cDNA encoding the mature part of the RET ectodomain was amplified by PCR and cloned into the SfiI and NotI sites of the pSecTag2AHA vector. The chimeric constructs were generated by splicing by overlap extension (19). The integrity of the cloning junctions of all constructs were confirmed by automated DNA sequencing. The regions targeted for mutation by en-bloc mutagenesis were identified using the GETAREA 1.1 software (20) (www.scsb.utmb.edu/getarea/area_man.html) with the coordinates from the modeled CLD (1–3) as input (17).

Transfection and Selection of Stable CHO Cell Lines—Chinese hamster ovary (CHO) cells were maintained in a humid atmosphere of 5% CO2 in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 2 mM L-glutamine and 60 µg/ml gentamycin and 10% fetal bovine serum. Freshly split CHO cells were transfected using FuGENE 6 with the different chimeric constructs. Forty-eight h after transfection, 800 µg/ml of hygromycin B (Invitrogen) was applied in complete Dulbecco's modified Eagle's medium. Colonies were picked within 1–2 weeks of selection and expanded in 96-well plates. The expression of RET protein was determined by Western blot using the anti-HA antibody B16.12 (Covance, Biosite) as primary antibody. Single clones were expanded for expression experiments.

Expression of Soluble Chimeric RETECD Proteins—Stably transfected CHO cells were expanded into 10-cm plates and allowed to reach 80% confluence. Subsequently, the serum-containing medium was removed, and the cells were rinsed twice with PBS. Serum-free medium consisting of Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine and 1 mM Hepes and 60 µg/ml gentamycin was added to the cells. To enhance the yield, prevent CHO cell proliferation, and alleviate potential misfolding routes during protein maturation, the CHO cells were expanded at 37 °C but shifted to 30 °C for the period of protein expression in serum-free medium as described previously (18). The incubation and protein production were continued for 3–4 days at +30 °C. The serum-free medium was concentrated using Centriprep-10 (Amicon). The concentration of the protein was determined either by Western blotting with anti-HA antibodies or by sandwich enzyme-linked immunosorbent assay using anti-HA antibodies as capture tools and a polyclonal rabbit anti-RETECD antibody (18) as detection reagent.

Deglycosylation Assays—To verify the structural integrity (and consequent ability of the molecules to pass the "quality control checkpoint" of the endoplasmic reticulum) of the RET domain chimeras and finetuned mutants, the chimeric RETECD mutants were subjected to deglycosylation assays using endoglycosidase H (Endo H) and peptide:N-glycosidase F (PNGase F) deglycosidases. Typically, 50 µl of conditioned medium was either treated with deglycosidase or left untreated. The deglycosylation was carried out according to instructions of the manufacturer (New England Biolabs).

Binding Assays—The binding experiments were performed essentially as described (18). Briefly, 50 ng of human GDNF (PeproTech) was mixed with 250 ng of a fusion protein formed by rat GFR{alpha}1 and the Fc domain of human IgG (GFR{alpha}1-Fc, R&D Systems) in PBS. In some experiments, the related ligand NTN (human) and the Fc fusion of its cognate GFR{alpha}2 receptor (from rat) were also used. After 5 min of incubation at room temperature, the protein solution was added to the wells of an enzyme-linked immunosorbent assay plate (MaxiSorp, Nunc). The following day, the wells were rinsed by PBS and blocked with 2% skimmed milk powder in TBS (2% MTBS) for 1 h at room temperature. Equal amounts of RETECD mutants were added to the GDNF-GFR{alpha}-1-Fc coated wells and to wells only coated with 2% MTBS. The binding was allowed to proceed for 1 h at room temperature. The washing was performed with TBS with 0.1% Tween 20 three times and TBS three times. Following washing, bound RETECD molecules were detected by a monoclonal anti-HA antibody at a 1:2000 dilution in 2% MTBS. Finally, the monoclonal anti-HA antibody was detected with an anti-mouse horseradish peroxidase-conjugated antibody (DAKO) at a 1:2000 dilution in MTBS. The reaction was developed by addition of 3,3',5,5'-tetramethyl benzidine (TMB) substrate according to the instructions of the manufacturer (Pierce).

Native Deglycosylation of Human RETECD and Binding Analysis—To examine the influence of the N-linked carbohydrates attached to the ectodomain of RET, the carbohydrates were enzymatically removed under native conditions. Briefly, 1 µg of semipurified HA-tagged RETECD was deglycosylated by incubation with 20 units of PNGase F overnight at 4 °C. Half of the reaction was applied for binding experiments as described above. The remaining portion was taken for Western blot analysis to verify the removal of N-linked carbohydrates.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Preferential Interaction of the Mammalian GDNF-GFR{alpha}-1 Ligand Complex with Human, but Not Xenopus, RETECD—To evaluate the functional capabilities of wild type and mutant RETECD molecules, we have developed a solid-phase binding assay using immobilized human GDNF, rat GFR{alpha}1, or the GDNF-GFR{alpha}1 complex as target ligands (18). Recombinant RETECD molecules were produced as epitope-tagged, soluble proteins in serum-free supernatants of stable transfected CHO cell lines as described previously (18). As shown in Fig. 1A, human RETECD was able to detect the GDNF-GFR{alpha}1 complex with an EC50 of ~0.2 nM, a value comparable with the binding affinity reported previously using cell-based cross-linking binding assays (10). The human RETECD did not interact with either GDNF or GFR{alpha}1 alone (Fig. 1A), in agreement with previous observations. Similar to cell-based binding assays (17, 21, 22), the interaction between the human RETECD and the GDNF-GFR{alpha}1 complex in our solid-phase binding assay was dependent on Ca2+, as it was totally abolished in the presence of 1 mM of the Ca2+-specific chelator EGTA (Fig. 1B). Based on its structural role in the cadherin molecule, the binding of Ca2+ ions to the CLD2/CLD3 interface of the RETECD is thought to rigidify the relative orientations of these two cadherin-like domains in RETECD (23, 24). The requirement of Ca2+ for the ability of the RETECD to interact with the GDNF-GFR{alpha}1 complex suggests that residues located on both sides of the Ca2+ binding site between CLD2 and CLD3 may contribute to ligand binding. Despite its overall structural similarity to human RETECD (17), the Xenopus RETECD has only 45% amino acid identity to its human counterpart, indicating a significant level of sequence divergence between the two species. In contrast, the intracellular domains of human and Xenopus RET display greater than 85% sequence identity. When compared with human RETECD, Xenopus RETECD showed negligible binding to the mammalian GDNF-GFR{alpha}1 complex in the concentration range tested (Fig. 1C), indicating that divergent regions between human and Xenopus RETECD may represent specific ligand binding determinants.



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1.
Preferential interaction of the mammalian GDNF-GFR{alpha}1 ligand complex with human, but not Xenopus, RETECD. A, solid-phase binding assay of human RETECD with immobilized human GDNF (open squares), rat GFR{alpha}1 (gray squares), or a GDNF-GFR{alpha}1 complex (solid squares). Shown are the means of triplicate observations. B, solid-phase binding assay of human RETECD with immobilized GDNF-GFR{alpha}1 complex in control conditions or in the presence of the Ca2+ chelator EGTA. Shown are the means of triplicate observations. C, solid-phase binding assay of human (solid squares) or Xenopus (gray squares) RETECD with immobilized GDNF-GFR{alpha}1. Shown are means ± S.D. of triplicate observations.

 
A Strategy for Homologue-scanning Mutagenesis of the Human RETECD—The inability of Xenopus RETECD to interact with the mammalian GDNF-GFR{alpha}1 complex despite its overall structural similarity to the human RETECD allowed us to use a homologue-scanning mutagenesis approach to study structure-function relationships in the RETECD. Based on the subdomain boundaries defined in a previous bioinformatics study on the RETECD (17), a series of chimeric molecules was constructed by swapping different subdomains between human and Xenopus RETECD (Fig. 2A). Stable CHO cell lines secreting different epitope-tagged chimeric Xenopus/human RETECD molecules were generated as described previously (18).



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 2.
CLD1, -2, and -3 of the human RETECD are required for binding to the mammalian GDNF-GFR{alpha}1 ligand complex. In A, chimeric RETECD constructs produced in supernatants of stably transfected CHO cells grown at 30 °C were subjected to deglycosylation as indicated. RETECD proteins were detected with an anti-HA antibody. Deglycosylation-resistant (solid arrowheads) and -sensitive (empty arrowheads) protein species are indicated. All constructs were sensitive to PNGase F digestion, as expected, but were largely resistant to Endo H. The diagram summarizes the chimeric molecules generated and their corresponding nomenclature. h, human; x, Xenopus. B, anti-HA tag blot of CHO cell supernatants showing that chimeric molecules were produced at comparable levels. IB, immunoblot. C, solid-phase binding assay of chimeric RETECD molecules. Wells were coated with GDNF-GFR{alpha}1-Fc complex (solid bars) or PBS (white bars) and subsequently blocked with low-fat milk. Results were normalized to the binding of wild type human RETECD. Control denotes supernatant from mock-transfected CHO cells. Shown are means ± S.D. of triplicate observations. D, solid-phase binding assay of chimeric RETECD molecules. Wells were coated with NTN-GFR{alpha}2-Fc complex (solid bars) or PBS (white bars) and subsequently blocked with low-fat milk. Shown are means ± S.D. of triplicate observations.

 
In a previous study, we found that certain subdomains of the RETECD, mainly CLD1, -2, and -3, have an intrinsic susceptibility to misfolding that makes them particularly vulnerable to inactivating mutations such as those found in patients with Hirschsprung disease (18). Misfolded RETECD molecules are retained intracellularly in the endoplasmic reticulum and eventually ubiquitinated and degraded, although a fraction may also get access to the extracellular space by direct leakage from the endoplasmic reticulum, particularly after overexpression (18). Folded and misfolded RETECD molecules can be distinguished by the sensitivity of the latter to Endo H (18). Upon exit from the endoplasmic reticulum, correctly folded glycoproteins lose sensitivity to Endo H as carbohydrates of higher complexity are added in the Golgi complex. The structural integrity of chimeric RETECD molecules was examined by subjecting the secreted proteins to Endo H treatment as described previously (18). As a control, RETECD proteins were treated with PNGase F, which removes sugars from both folded and misfolded proteins. As shown in Fig. 2A, all chimeric RETECD proteins were resistant to Endo H treatment (solid arrowheads) but were still sensitive to PNGase F as expected (open arrowheads). These results indicated that this set of Xenopus/human chimeric RETECD molecules was folded correctly.

CLD1, -2, and -3 of the Human RETECD Are Required for Binding to the Mammalian GDNF-GFR{alpha}1 Ligand Complex— The ligand binding activity of chimeric RETECD proteins was evaluated using a solid-phase binding assay with the GDNF-GFR{alpha}1 complex immobilized to 96-well plates. Chimeric molecules were also tested against a complex formed by human NTN and rat GFR{alpha}2. Equivalent levels of wild type and chimeric proteins were present in these experiments as demonstrated by Western blotting using an antibody against the HA epitope tag present in all the constructs (Fig. 2B). Xenopus RETECD was not able to interact with the NTN-GFR{alpha}2 complex (data not shown). As shown in Fig. 2, C and D, binding activity to either ligand complex required all three N-terminal cadherin-like domains of RETECD (i.e. CLD1, -2, and -3) to be of human origin. In contrast, the species of origin of CLD4 and the cysteine-rich domain had no impact on the ligand binding activity of chimeric RETECD molecules (Fig. 2, C and D). Similar structure-activity profiles were observed toward both GDNF-GFR{alpha}1 and NTN-GFR{alpha}2 complexes, indicating that the RETECD interacts with different members of the GDNF and GFR{alpha} families in a similar fashion. The fact that residues on both sides of the Ca2+ coordination site were required for ligand binding is in agreement with the recognized importance of Ca2+ for stabilizing the RETECD in a conformation competent for ligand binding and receptor activation (Fig. 1B) (17, 22).

Distinct Clusters of Exposed Residues in CLD1 Are Required for Binding of Human RETECD to the GDNF-GFR{alpha}1 Complex— Having established the existence of ligand binding determinants within CLD1, -2, and -3 of the human RETECD, we set out to define more precisely the location and identity of functionally important residues in these three domains. The GETAREA 1.1 program (www.scsb.utmb.edu/getarea/area_man.html) was used to generate surface accessibility plots of CLD1, -2, and -3 of the human RETECD using the coordinates of their modeled structures (17) (see the supplemental figure). Segments displaying more than 50% surface accessibility were examined for their degree of sequence similarity to analogous segments in the Xenopus RETECD. Exposed segments of 6–12 residues in CLD1, -2, and -3 of the human RETECD displaying more than 50% divergence from the equivalent Xenopus sequences were targeted for a second round of homologue-scanning mutagenesis (Fig. 3A). A total of 10 chimeric constructs (designated with the Roman numerals I–X) were generated and produced in the supernatants of stable CHO cell transfectants as above (Fig. 3B). With the exception of chimeric protein X, all other chimeras were resistant to Endo H digestion and therefore considered correctly folded (Fig. 3B). Equivalent amounts of wild type human RETECD and chimeric proteins I–IX (Fig. 3C) were compared for their ability to bind the mammalian GDNF-GFR{alpha}1 complex in a solid-phase based binding assay as above. As shown in Fig. 3D, chimeras I, III, IV, V, and VI all displayed a reduction in binding as compared with the wild type human RETECD.



View larger version (46K):
[in this window]
[in a new window]
  		FIG. 3.
Distinct clusters of exposed residues in CLD1 are required for binding of human RETECD to the GDNF-GFR{alpha}1 complex. A, alignment of the human and Xenopus RETECD with conserved residues boxed in black, and surface-exposed, variable regions used to produce chimeric molecules boxed in gray. hRet, human RET; xRet, Xenopus RET. In B, chimeric RETECD constructs produced in supernatants of stably transfected CHO cells grown at 30 °C were subjected to deglycosylation as indicated. RETECD proteins were detected with an anti-HA antibody. Deglycosylation-resistant (solid arrowheads) and -sensitive (empty arrowheads) species are indicated. All constructs were sensitive to PNGase F digestion, as expected. Constructs I–IX were largely resistant to Endo H, whereas construct X was sensitive, indicating a misfolded protein. The diagram summarizes the chimeric molecules generated and their corresponding nomenclature. C, anti-HA tag blot of CHO cell supernatants showing that wild type hRETECD and chimeric molecules I–IX were produced at comparable levels. IB, immunoblot. D, solid-phase binding assay of chimeric RETECD molecules. Wells were coated with GDNF-GFR{alpha}1-Fc complex (solid bars) or PBS (white bars) and subsequently blocked with low-fat milk. Results were normalized to the binding of wild type human RETECD. Control denotes supernatant from mock-transfected CHO cells. Shown are means ± S.D. of triplicate observations.

 
Chimeric protein I carries 4 amino acid replacements as compared with wild type human RETECD, namely S32L, D34K, A35D, and W37Y, suggesting that one or more of those positions are crucial for the interaction of the RETECD with the GDNF-GFR{alpha}1 complex. Based on the modeled structure of CLD1 (17), residues in region III are predicted to form part of a loop between the C and D {beta}-strands of this domain. This exposed segment is shorter and highly divergent in the Xenopus RETECD, indicating that residues in this loop region may also contribute to the binding of the human RETECD to the GDNF-GFR{alpha}1 complex.

In contrast to chimeras I, III, and V, chimeric protein IV retained ~20% binding to the GDNF-GFR{alpha}1 complex (Fig. 3D). Of the 8 amino acid exchanges in this region, three involve the replacement of positively charged residues by uncharged residues (Fig. 3A), indicating that one or more of those charges are important for formation of the GDNF-GFR{alpha}1-RET complex. The complete absence of detectable binding in chimeric protein V indicates that one or more of the residues exchanged in this region are important for ligand binding. Of the 9 amino acid differences between the human and Xenopus sequences in this region, R133L and W139N may be the most significant ones as they involve residues that are enriched in known protein-protein interfaces (25). Finally, a 60% reduction in ligand binding was observed in chimeric protein VI (Fig. 3D), which involves 9 amino acid replacements in CLD2 (Fig. 3A). Of note, this was the only set of mutations outside CLD1 that affected the interaction of the RETECD with the GDNF-GFR{alpha}1 complex. Interestingly, three of the exchanges in this region involve the replacement of two polar and one uncharged residue by positively charged residues (Fig. 3A). Taken together, they indicate that although CLD1, -2, and -3 of human RETECD are all required for ligand binding, the most important determinants appear to be concentrated in CLD1, the most N-terminal subdomain of the human RETECD.

N-linked Carbohydrates in Human RETECD Are Dispensable for Ligand Binding—Protein glycosylation can have a modulatory effect on protein-protein interactions, and introduction of N-linked glycosylation sites has been used as a mutagenesis strategy (26). The human RETECD is abundantly N-glycosylated, but the role of this post-translational modification in ligand binding is unknown. Interestingly, predicted N-glycosylation sites in the human RETECD are not evenly distributed, but the majority (9 of 12) of them appear downstream of the Ca2+ coordination site, in accord with the location of ligand binding determinants in the CLD1. We treated the human RETECD with PNGase F under native conditions and examined its ability to bind to the GDNF-GFR{alpha}1 complex. Treatment with PNGase F resulted in complete deglycosylation of the native protein, comparable with that obtained after prior denaturation (Fig. 4A). As shown in Fig. 4B, RETECD incubated in deglycosylation buffer with or without PNGase F without prior denaturation showed no loss of binding as compared with a non-treated control. Denaturation prior to enzymatic deglycosylation resulted in complete loss of binding, as expected (Fig. 4B). Thus, N-linked carbohydrates are unlikely to play a role in the assembly of the RET-GDNF-GFR{alpha}1 complex and may instead be of importance for the folding and maturation of the RETECD in the secretory pathway, as suggested previously (18).



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 4.
N-linked carbohydrates in human RETECD are dispensable for ligand binding. In A, equal amounts of human RETECD were subjected to an incubation in the presence or absence of PNGase F under native or denaturing conditions as indicated. Untreated RETECD was used as control. IB, immunoblot. B, solid-phase binding assay of native and denatured human RETECD after treatment with PNGase as above. Wells were coated with GDNF-GFR{alpha}1-Fc complex. Shown are means ± S.D. of triplicate observations.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The receptor tyrosine kinase RET has remained in the limelight ever since its discovery as a transforming protein in 1987 (27) and the subsequent elucidation of its participation in the receptor complex for GDNF family ligands (10, 28, 29). Despite having an extracellular domain of more than 600 residues, RET cannot engage any of these ligands directly but requires the auxiliary GFR{alpha} receptors for activation (29, 30). Although the RETECD was known to make direct contacts with both GDNF ligands and GFR{alpha} receptors in the complex, binding determinants in the RETECD molecule and the overall architecture of the complex remained to be characterized.

In this study, we set out to identify functional determinants in the RETECD responsible for its association with the GDNF-GFR{alpha}1 complex using a homologue-scanning mutagenesis approach based on the differential abilities of human and Xenopus RETECD to interact with ligand complexes of mammalian origin. Using this approach, binding determinants were found to be concentrated in the N-terminal CLD1 of the human RETECD. Within this region, three discrete segments, ranging from 6 to 12 residues (i.e. I, III, and V in Fig. 3A), could not be replaced by equivalent sequences from Xenopus RETECD without complete loss of activity, indicating that these segments are required for the binding of the human RETECD to the mammalian GDNF-GFR{alpha}1 complex. Importantly, these replacements had no detectable effects on protein production, stability, secretion, or folding, at least at 30 °C. Because of their relatively high solvent accessibility, these epitopes are likely to be directly involved in the interaction of RET with its ligands. When visualized on the modeled three-dimensional structure of the CLD1 (17), regions I, III, and V are all localized on the same face of the model (Fig. 5A), delineating a probable surface for interaction with the GDNF-GFR{alpha}1 complex. In support of this notion, the only site of N-glycosylation known in the human CLD1, namely Asn-98,2 is located in the opposite side of the domain, a position that is sterically compatible with the proposed location of the ligand binding interface.



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 5.
Identification of a surface for binding to the GDNF-GFR{alpha}1 complex in the RETECD. A, RasMol (36) representation of the CLD1 of the RETECD based on the coordinates described by Anders et al. (17). Clusters of mutated residues that resulted in complete lack-of-binding of human RETECD are colored in red (region I), yellow (region III), and blue (region V). Coordinates of the models described in Anders et al. (17) are available upon request. B, diagram of a tentative model of the ternary complex formed by RET, GFR{alpha}1, and GDNF. Although dimers of RET and GFR{alpha}1 are believed to interact with the dimeric GDNF ligand, only one of the protomers is shown here for clarity.

 

Bioinformatics analysis of the RETECD has recently indicated a structural organization resembling that of classical cadherins with four cadherin-like domains followed by a C-terminal cysteine-rich domain not related to cadherin sequences (17). The x-ray crystal structure of the complete extracellular domain of C-cadherin has recently been solved, revealing an elongated rod-shaped structure (24). Two types of interactions between different cadherin molecules could be defined in these crystals: cis interactions were formed laterally between adjacent cadherin molecules, whereas trans interactions linked cadherin molecules in opposite orientations, presumably representing the kind of interactions responsible for cell-cell contact. The trans interface was defined by a conserved tryptophan side chain (Trp-2) at the N-terminal end of the cadherin molecule from one cell, which was shown to insert into a hydrophobic pocket in the cadherin molecule from the opposing cell (24). The importance of Trp-2 for cadherin-mediated cell adhesion had been inferred independently from structure-function analyses (31). However, Trp-2 is not conserved in RETECD sequences from different organisms, and no functionally analogous residues can be identified in the modeled structure of the RETECD (17). Moreover, no adhesive function has to date been attributed to RET molecules (32).

Given the pivotal role played by the CLD1 in the interaction of RET with its ligands, a straight rod-like organization similar to that of classical cadherins would place the major ligand binding site in the RETECD away from the plasma membrane, where the membrane-anchored GDNF-GFR{alpha}1 complex is likely to be. In fact, structure-function studies of the GFR{alpha}1 molecule have indicated that the N-terminal domain of this receptor is dispensable for ligand binding and have instead localized the binding determinants toward the middle and C-terminal portions of the molecule (12), in agreement with a membrane-proximal site of complex assembly. How could these apparently contradictory observations be reconciled?

An analogous topological problem has been posed by the cytokine receptor complex formed by gp130, IL-6R{alpha}, and IL-6. Like RET, gp130 has a large multidomain extracellular region, and ligand binding determinants have been localized to the three most N-terminal domains (33). On the other hand, IL-6R{alpha}, like GFR{alpha}1, has ligand binding determinants in its membrane-proximal domains (34). A recent crystallographic analysis of the assembly of this complex revealed a bent structure for gp130 and IL-6R with their ligand binding domains forming a "table" that rests on "legs" composed by the more C-terminal domains of the molecules (35). In an analogous fashion, we hypothesize that a bent arrangement of the RETECD would allow its ligand binding domain to reach the GDNF-GFR{alpha}1 complex located closer to the membrane (Fig. 5B). It is worth noting that this arrangement would not be possible had the RETECD retained all the interdomain Ca2+ binding sites that characterize classical cadherins. As mentioned previously, the single Ca2+ binding site in the RETECD is located at the interface of CLD2 and CLD3, suggesting a straight and rigid conformation for these two domains. On the other hand, the lack of Ca2+ binding sites in all of the other interdomain regions suggest a greater degree of flexibility as compared with classical cadherins that may allow the RETECD to bend toward the cell membrane. Clearly, validation of this hypothesis awaits the structural determination of the RETECD in complex with GFR{alpha}1 and GDNF.


   FOOTNOTES
 
* This work was supported by grants from the Swedish Foundation for Strategic Research, the Swedish Medical Research Council (K99-33X-10908-06C), the Vth Framework Program of the European Union (QLRT-1999-00099), Centrala Försökdjursnämnden, the Swedish Fund for Research without Laboratory Animals, and the Karolinska Institute. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

The on-line version of this article (available at http://www.jbc.org) contains a supplementary figure showing surface accessibility plots of CLDs 1, 2, and 3 of the human RETECD. Back

{ddagger} To whom correspondence should be addressed. carlos.ibanez{at}neuro.ki.se.

1 The abbreviations used are: GDNF, glial cell line-derived neurotrophic factor; GFR{alpha}a, GDNF-family receptor-{alpha}; NTN, neurturin; CLD, cadherin-like domains; HA, hemagglutinin; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; PNGase F, peptide:N-glycosidase F; Endo H, endoglycosidase H. Back

2 S Kjær, unpublished observations. Back


   ACKNOWLEDGMENTS
 
We thank Mart Saarma for the mouse RET cDNA, P. J. Long for the Xenopus RET cDNA, Anatoly Sharipo for anti-RETECD antibodies, and Xiaoli Li for secretarial help.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Lin, L.-F., Doherty, D. H., Lile, J. D., Bektesh, S., and Collins, F. (1993) Science 260, 1130–1132[Abstract/Free Full Text]
  2. Gash, D. M., Zhang, Z., and Gerhardt, G. (1998) Ann. Neurol. 44, Suppl. 1, S121–S125[Medline] [Order article via Infotrieve]
  3. Eigenbrot, C., and Gerber, N. (1997) Nat. Struct. Biol. 4, 435–438[CrossRef][Medline] [Order article via Infotrieve]
  4. Airaksinen, M. S., and Saarma, M. (2002) Nat. Rev. Neurosci. 3, 383–394[CrossRef][Medline] [Order article via Infotrieve]
  5. Baloh, R. H., Enomoto, H., Johnson, E. M., Jr., and Milbrandt, J. (2000) Curr. Opin. Neurobiol. 10, 103–110[CrossRef][Medline] [Order article via Infotrieve]
  6. Paratcha, G., Ledda, F., and Ibáñez, C. F. (2003) Cell 113, 867–879[CrossRef][Medline] [Order article via Infotrieve]
  7. Edery, P., Eng, C., Munnich, A., and Lyonnet, S. (1997) BioEssays 19, 389–395[CrossRef][Medline] [Order article via Infotrieve]
  8. Santoro, M., Carlomagno, F., Melillo, R. M., Billaud, M., Vecchio, G., and Fusco, A. (1999) J. Endocrinol. Investig. 22, 811–819[Medline] [Order article via Infotrieve]
  9. Carlomagno, F., Devita, G., Berlingieri, M. T., Defranciscis, V., Melillo, R. M., Colantuoni, V., Kraus, M. H., Difiore, P. P., Fusco, A., and Santoro, M. (1996) EMBO J. 15, 2717–2725[Medline] [Order article via Infotrieve]
  10. Trupp, M., Arenas, E., Fainzilber, M., Nilsson, A.-S., Sieber, B. A., Grigoriou, M., Kilkenny, C., Salazar-Grueso, E., Pachnis, V., Arumäe, U., Sariola, H., Saarma, M., and Ibáñez, C. F. (1996) Nature 381, 785–789[CrossRef][Medline] [Order article via Infotrieve]
  11. Trupp, M., Raynoschek, C., Belluardo, N., and Ibáñez, C. F. (1998) Mol. Cell Neurosci. 11, 47–63[CrossRef][Medline] [Order article via Infotrieve]
  12. Scott, R. P., and Ibáñez, C. F. (2001) J. Biol. Chem. 276, 1450–1458[Abstract/Free Full Text]
  13. Eketjäll, S., Fainzilber, M., Murray-Rust, J., and Ibáñez, C. F. (1999) EMBO J. 18, 5901–5910[CrossRef][Medline] [Order article via Infotrieve]
  14. Baloh, R. H., Tansey, M. G., Johnson, E. M., and Milbrandt, J. (2000) J. Biol. Chem. 275, 3412–3420[Abstract/Free Full Text]
  15. Shi, Y. G., and Massague, J. (2003) Cell 113, 685–700[CrossRef][Medline] [Order article via Infotrieve]
  16. Sanicola, M., Hession, C., Worley, D., Carmillo, P., Ehrenfels, C., Walus, L., Robinson, S., Jaworski, G., Wei, H., Tizard, R., Whitty, A., Pepinsky, R. B., and Cate, R. L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6238–6243[Abstract/Free Full Text]
  17. Anders, J., Kjær, S., and Ibáñez, C. F. (2001) J. Biol. Chem. 276, 35808–35817[Abstract/Free Full Text]
  18. Kjær, S., and Ibáñez, C. F. (2003) Hum. Mol. Genet. 12, 2133–2144[Abstract/Free Full Text]
  19. Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 61–68[CrossRef][Medline] [Order article via Infotrieve]
  20. Fraczkiewicz, R., and Braun, W. (1998) J. Comput. Chem. 19, 319–333[CrossRef]
  21. van Weering, D., Moen, T. C., Braakman, I., Baas, P. D., and Bos, J. L. (1998) J. Biol. Chem. 273, 12077–12081[Abstract/Free Full Text]
  22. Nozaki, C., Asai, N., Murakami, H., Iwashita, T., Iwata, Y., Horibe, K., Klein, R. D., Rosenthal, A., and Takahashi, M. (1998) Oncogene 16, 293–299[CrossRef][Medline] [Order article via Infotrieve]
  23. Nagar, B., Overduin, M., Ikura, M., and Rini, J. M. (1996) Nature 380, 360–364[CrossRef][Medline] [Order article via Infotrieve]
  24. Boggon, T. J., Murray, J., Chappuis-Flament, S., Wong, E., Gumbiner, B. M., and Shapiro, L. (2002) Science 296, 1308–1313[Abstract/Free Full Text]
  25. Bogan, A. A., and Thorn, K. S. (1998) J. Mol. Biol. 280, 1–9[CrossRef][Medline] [Order article via Infotrieve]
  26. Steen, M., Villoutreix, B. O., Norstrom, E. A., Yamazaki, T., and Dahlback, B. (2002) J. Biol. Chem. 277, 50022–50029[Abstract/Free Full Text]
  27. Takahashi, M., and Cooper, G. M. (1987) Mol. Cell Biol. 7, 1378–1385[Abstract/Free Full Text]
  28. Durbec, P., Marcos-Gutierrez, C. V., Kilkenny, C., Grigoriou, M., Suvanto, P., Wartiovaara, K., Smith, D., Ponder, B., Costantini, F., Saarma, M., Sariola, H., and Pachnis, V. (1996) Nature 381, 789–792[CrossRef][Medline] [Order article via Infotrieve]
  29. Jing, S. Q., Wen, D. Z., Yu, Y. B., Holst, P. L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., Louis, J. C., Hu, S., Altrock, B. W., and Fox, G. M. (1996) Cell 85, 1113–1124[CrossRef][Medline] [Order article via Infotrieve]
  30. Treanor, J., Goodman, L., Desauvage, F., Stone, D. M., Poulsen, K. T., Beck, C. D., Gray, C., Armanini, M. P., Pollock, R. A., Hefti, F., Phillips, H. S., Goddard, A., Moore, M. W., Buj-Bello, A., Davies, A. M., Asai, N., Takahashi, M., Vandlen, R., Henderson, C. E., and Rosenthal, A. (1996) Nature 382, 80–83[CrossRef][Medline] [Order article via Infotrieve]
  31. Tamura, K., Shan, W. S., Hendrickson, W. A., Colman, D. R., and Shapiro, L. (1998) Neuron 20, 1153–1163[CrossRef][Medline] [Order article via Infotrieve]
  32. Takahashi, M., Asai, N., Iwashita, T., Isomura, T., Miyazaki, K., and Matsuyama, M. (1993) Oncogene 8, 2925–2929[Medline] [Order article via Infotrieve]
  33. Hammacher, A., Richardson, R. T., Layton, J. E., Smith, D. K., Angus, L. J., Hilton, D. J., Nicola, N. A., Wijdenes, J., and Simpson, R. J. (1998) J. Biol. Chem. 273, 22701–22707[Abstract/Free Full Text]
  34. Yawata, H., Yasukawa, K., Natsuka, S., Murakami, M., Yamasaki, K., Hibi, M., Taga, T., and Kishimoto, T. (1993) EMBO J. 12, 1705–1712[Medline] [Order article via Infotrieve]
  35. Boulanger, M. J., Chow, D. C., Brevnova, E. E., and Garcia, K. C. (2003) Science 300, 2101–2104[Abstract/Free Full Text]
  36. Sayle, R., and Milner-White, E. (1995) Trends Biochem. Sci. 20, 374–376[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Endocr. Rev., August 1, 2006; 27(5): 535 - 560.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
I. Ben-Shlomo and A. J. W. Hsueh
Three's Company: Two or More Unrelated Receptors Pair with the Same Ligand
Mol. Endocrinol., May 1, 2005; 19(5): 1097 - 1109.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
278/48/47898    most recent
M309772200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kjær, S.
Right arrow Articles by Ibáñez, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kjær, S.
Right arrow Articles by Ibáñez, C. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME